샘플 요청 목록

 카트 문의
시장보고서
상품코드
1873681

세계의 주의력 결핍 과잉행동장애(ADHD) : 시장 점유율과 순위, 전체 판매량 및 수요 예측(2025-2031년)

Attention Deficit Hyperactivity Disorder (ADHD) - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
발행일: | 리서치사: QYResearch | 페이지 정보: 영문 | 배송안내 : 2-3일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

세계의 주의력 결핍 과잉행동장애(ADHD) 시장 규모는 2024년에 134억 3,000만 달러로 추정되며, 2025-2031년의 예측 기간에 CAGR 4.9%로 성장하여 2031년까지 185억 5,000만 달러로 확대될 것으로 예측됩니다.

ADHD의 효과적인 치료. ADHD는 어린 시절에 발병하는 증후군군을 말하며, 동년배 아이들에 비해 뚜렷한 집중력 저하, 짧은 주의력 지속시간, 과잉행동 또는 충동성을 특징으로 합니다.

ADHD 시장은 전 세계적으로 인지도 향상과 진단율 증가, 특히 소아 및 젊은 성인층에서 빠르게 성장하고 있습니다. 의료진, 교육자, 보호자의 정신 건강 상태에 대한 이해도가 높아짐에 따라 조기 발견과 보다 적극적인 치료 접근에 기여하고 있습니다. 정부 지원, 학교 내 정신 건강 검진, 보험 적용 범위 확대로 선진국과 개발도상국 모두에서 ADHD 치료에 대한 접근성이 향상되었습니다. 또한, 약리학 연구의 발전으로 보다 효과적이고 오래 지속되며 내약성이 좋은 약물이 개발되어 치료 선택의 폭이 넓어지고 있습니다. 원격 의료 및 증상 모니터링용 모바일 앱을 포함한 디지털 헬스 플랫폼의 등장으로 ADHD 관리가 더욱 편리하고 효율적으로 이루어지고 있습니다. 공공 토론 증가와 편견의 감소에 힘입어 성인 ADHD 진단 증가도 시장 성장에 더욱 기여하고 있습니다.

수요 증가에도 불구하고 ADHD 시장은 몇 가지 심각한 문제에 직면해 있습니다. 주요 우려 사항 중 하나는 특히 소아에서 ADHD의 과잉 진단 및 오진 가능성이 있으며, 이는 부적절하거나 과도한 약물 사용으로 이어질 수 있다는 점입니다. ADHD를 불안장애, 자폐증, 학습장애 등 다른 행동 및 심리장애와 구별하는 것은 여전히 복잡하며, 많은 경우 다학제적 평가가 필요합니다. 불면증, 식욕억제, 심혈관계 부작용 등 약물의 부작용은 치료의 비순응이나 중단으로 이어질 수 있습니다. 또한, 남용과 의존의 가능성으로 인해 자극제 처방에 대한 규제 장벽도 존재합니다. 또한, 저소득 지역과 지방의 의료 인프라 격차, 숙련된 정신보건 전문가에 대한 접근성 제한으로 인해 적시에 진단과 치료가 이루어지지 못하고 있습니다. 정신질환에 대한 문화적 편견은 여전히 많은 개인과 가족들이 의료 지원을 받는 것을 주저하게 만들고 있으며, 특히 신흥 시장에서는 더욱 그렇다.

이 보고서는 주의력결핍 및 과잉행동장애(ADHD) 세계 시장에 대해 총 매출액, 주요 기업의 시장 점유율 및 순위를 중심으로 지역별, 국가별, 유형별, 유통 채널별 분석을 종합적으로 제시하는 것을 목적으로 합니다.

이 보고서는 주의력결핍 및 과잉행동장애(ADHD) 시장 규모, 추정치, 예측치를 매출액 기준으로 제시하고, 2024년을 기준 연도로 하여 2020년부터 2031년까지의 과거 데이터와 예측 데이터를 포함하고 있습니다. 정량적 분석과 정성적 분석을 통해 독자들이 비즈니스/성장 전략을 수립하고, 시장 경쟁 구도를 평가하고, 현재 시장에서의 위치를 분석하고, 주의력결핍 및 과잉행동장애(ADHD)에 대한 정보에 입각한 비즈니스 의사결정을 내릴 수 있도록 돕습니다.

시장 세분화

기업별

  • Takeda
  • Johnson & Johnson
  • Novartis
  • Eli Lilly
  • Tris Pharma
  • Neos Therapeutics
  • Mallinckrodt
  • Amneal Pharmaceuticals
  • Noven Pharmaceuticals
  • Purdue Parma
  • Zhengdafenhai
  • Highland Therapeutics
  • Jubilant Life Sciences
  • Medice Arzneimittel Putter
  • Lannett

유형별 부문

  • 자극제
  • 비자극제

유통 채널별 부문

  • 병원 약국
  • 소매 약국

지역별

  • 북미
    • 미국
    • 캐나다
  • 아시아태평양
    • 중국
    • 일본
    • 한국
    • 동남아시아
    • 인도
    • 호주
    • 기타 아시아태평양
  • 유럽
    • 독일
    • 프랑스
    • 영국
    • 이탈리아
    • 네덜란드
    • 북유럽 국가
    • 기타 유럽
  • 라틴아메리카
    • 멕시코
    • 브라질
    • 기타 라틴아메리카
  • 중동 및 아프리카
    • 튀르키예
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 기타 중동 및 아프리카
LSH 25.12.05

자주 묻는 질문

  • 2024년 ADHD 시장 규모는 어떻게 되며, 향후 성장 전망은 어떤가요?
  • ADHD 치료에 대한 접근성이 향상된 이유는 무엇인가요?
  • ADHD 시장에서의 주요 기업은 어디인가요?
  • ADHD 시장의 주요 세분화 기준은 무엇인가요?
  • ADHD 시장이 직면한 주요 문제는 무엇인가요?

The global market for Attention Deficit Hyperactivity Disorder (ADHD) was estimated to be worth US$ 13430 million in 2024 and is forecast to a readjusted size of US$ 18550 million by 2031 with a CAGR of 4.9% during the forecast period 2025-2031.

Effective treatment of ADHD. ADHD refers to a group of syndromes that occur in childhood and are characterized by obvious difficulty in concentration, short duration of attention, hyperactivity or impulsivity compared with children of the same age.

The ADHD market is expanding rapidly due to rising global awareness and increasing diagnosis rates, especially in children and young adults. Improved understanding of mental health conditions among healthcare providers, educators, and parents has contributed to earlier identification and more proactive treatment approaches. Government-supported initiatives, mental health screenings in schools, and expanded insurance coverage have made ADHD treatment more accessible in both developed and developing regions. Furthermore, advancements in pharmacological research have led to the availability of more effective, long-acting, and better-tolerated medications, expanding the range of treatment options. The rise of digital health platforms, including telemedicine and mobile apps for symptom monitoring, has also made ADHD management more convenient and efficient. Growing adult ADHD diagnosis, driven by increased public discussion and reduced stigma, is further contributing to market growth.

Despite the increasing demand, the ADHD market faces several significant challenges. One of the main concerns is the potential overdiagnosis or misdiagnosis of ADHD, particularly in children, leading to inappropriate or excessive use of medications. Differentiating ADHD from other behavioral or psychological disorders like anxiety, autism, or learning disabilities remains complex, often requiring multidisciplinary assessments. Medication side effects, such as insomnia, appetite suppression, and cardiovascular concerns, can lead to treatment non-compliance or discontinuation. There are also regulatory barriers around stimulant drug prescriptions due to their potential for abuse and dependency. Additionally, disparities in healthcare infrastructure and limited access to trained mental health professionals in low-income and rural areas hinder timely diagnosis and treatment. Cultural stigma around psychiatric disorders still discourages many individuals and families from seeking medical help, especially in emerging markets.

This report aims to provide a comprehensive presentation of the global market for Attention Deficit Hyperactivity Disorder (ADHD), focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Attention Deficit Hyperactivity Disorder (ADHD) by region & country, by Type, and by Distribution Channel.

The Attention Deficit Hyperactivity Disorder (ADHD) market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Attention Deficit Hyperactivity Disorder (ADHD).

Market Segmentation

By Company

  • Takeda
  • Johnson & Johnson
  • Novartis
  • Eli Lilly
  • Tris Pharma
  • Neos Therapeutics
  • Mallinckrodt
  • Amneal Pharmaceuticals
  • Noven Pharmaceuticals
  • Purdue Parma
  • Zhengdafenhai
  • Highland Therapeutics
  • Jubilant Life Sciences
  • Medice Arzneimittel Putter
  • Lannett

Segment by Type

  • Stimulant
  • Non-stimulant

Segment by Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Attention Deficit Hyperactivity Disorder (ADHD) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Distribution Channel, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Attention Deficit Hyperactivity Disorder (ADHD) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Attention Deficit Hyperactivity Disorder (ADHD) in country level. It provides sigmate data by Type, and by Distribution Channel for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Attention Deficit Hyperactivity Disorder (ADHD) Product Introduction
  • 1.2 Global Attention Deficit Hyperactivity Disorder (ADHD) Market Size Forecast (2020-2031)
  • 1.3 Attention Deficit Hyperactivity Disorder (ADHD) Market Trends & Drivers
    • 1.3.1 Attention Deficit Hyperactivity Disorder (ADHD) Industry Trends
    • 1.3.2 Attention Deficit Hyperactivity Disorder (ADHD) Market Drivers & Opportunity
    • 1.3.3 Attention Deficit Hyperactivity Disorder (ADHD) Market Challenges
    • 1.3.4 Attention Deficit Hyperactivity Disorder (ADHD) Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Players Revenue Ranking (2024)
  • 2.2 Global Attention Deficit Hyperactivity Disorder (ADHD) Revenue by Company (2020-2025)
  • 2.3 Key Companies Attention Deficit Hyperactivity Disorder (ADHD) Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Attention Deficit Hyperactivity Disorder (ADHD) Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Attention Deficit Hyperactivity Disorder (ADHD)
  • 2.6 Attention Deficit Hyperactivity Disorder (ADHD) Market Competitive Analysis
    • 2.6.1 Attention Deficit Hyperactivity Disorder (ADHD) Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Attention Deficit Hyperactivity Disorder (ADHD) Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Attention Deficit Hyperactivity Disorder (ADHD) as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Stimulant
    • 3.1.2 Non-stimulant
  • 3.2 Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Type
    • 3.2.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, by Type (2020-2031)
    • 3.2.3 Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, by Type (%) (2020-2031)

4 Segmentation by Distribution Channel

  • 4.1 Introduction by Distribution Channel
    • 4.1.1 Hospital Pharmacy
    • 4.1.2 Retail Pharmacy
  • 4.2 Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Distribution Channel
    • 4.2.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Distribution Channel (2020 VS 2024 VS 2031)
    • 4.2.2 Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, by Distribution Channel (2020-2031)
    • 4.2.3 Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, by Distribution Channel (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Region
    • 5.1.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Region (2020-2025)
    • 5.1.3 Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Region (2026-2031)
    • 5.1.4 Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, 2020-2031
    • 5.2.2 North America Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, 2020-2031
    • 5.3.2 Europe Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, 2020-2031
    • 5.5.2 South America Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Attention Deficit Hyperactivity Disorder (ADHD) Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, 2020-2031
    • 6.3.2 United States Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Distribution Channel, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, 2020-2031
    • 6.4.2 Europe Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Distribution Channel, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, 2020-2031
    • 6.5.2 China Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Distribution Channel, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, 2020-2031
    • 6.6.2 Japan Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Distribution Channel, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, 2020-2031
    • 6.7.2 South Korea Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Distribution Channel, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Distribution Channel, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, 2020-2031
    • 6.9.2 India Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Distribution Channel, 2024 VS 2031

7 Company Profiles

  • 7.1 Takeda
    • 7.1.1 Takeda Profile
    • 7.1.2 Takeda Main Business
    • 7.1.3 Takeda Attention Deficit Hyperactivity Disorder (ADHD) Products, Services and Solutions
    • 7.1.4 Takeda Attention Deficit Hyperactivity Disorder (ADHD) Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Takeda Recent Developments
  • 7.2 Johnson & Johnson
    • 7.2.1 Johnson & Johnson Profile
    • 7.2.2 Johnson & Johnson Main Business
    • 7.2.3 Johnson & Johnson Attention Deficit Hyperactivity Disorder (ADHD) Products, Services and Solutions
    • 7.2.4 Johnson & Johnson Attention Deficit Hyperactivity Disorder (ADHD) Revenue (US$ Million) & (2020-2025)
    • 7.2.5 Johnson & Johnson Recent Developments
  • 7.3 Novartis
    • 7.3.1 Novartis Profile
    • 7.3.2 Novartis Main Business
    • 7.3.3 Novartis Attention Deficit Hyperactivity Disorder (ADHD) Products, Services and Solutions
    • 7.3.4 Novartis Attention Deficit Hyperactivity Disorder (ADHD) Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Novartis Recent Developments
  • 7.4 Eli Lilly
    • 7.4.1 Eli Lilly Profile
    • 7.4.2 Eli Lilly Main Business
    • 7.4.3 Eli Lilly Attention Deficit Hyperactivity Disorder (ADHD) Products, Services and Solutions
    • 7.4.4 Eli Lilly Attention Deficit Hyperactivity Disorder (ADHD) Revenue (US$ Million) & (2020-2025)
    • 7.4.5 Eli Lilly Recent Developments
  • 7.5 Tris Pharma
    • 7.5.1 Tris Pharma Profile
    • 7.5.2 Tris Pharma Main Business
    • 7.5.3 Tris Pharma Attention Deficit Hyperactivity Disorder (ADHD) Products, Services and Solutions
    • 7.5.4 Tris Pharma Attention Deficit Hyperactivity Disorder (ADHD) Revenue (US$ Million) & (2020-2025)
    • 7.5.5 Tris Pharma Recent Developments
  • 7.6 Neos Therapeutics
    • 7.6.1 Neos Therapeutics Profile
    • 7.6.2 Neos Therapeutics Main Business
    • 7.6.3 Neos Therapeutics Attention Deficit Hyperactivity Disorder (ADHD) Products, Services and Solutions
    • 7.6.4 Neos Therapeutics Attention Deficit Hyperactivity Disorder (ADHD) Revenue (US$ Million) & (2020-2025)
    • 7.6.5 Neos Therapeutics Recent Developments
  • 7.7 Mallinckrodt
    • 7.7.1 Mallinckrodt Profile
    • 7.7.2 Mallinckrodt Main Business
    • 7.7.3 Mallinckrodt Attention Deficit Hyperactivity Disorder (ADHD) Products, Services and Solutions
    • 7.7.4 Mallinckrodt Attention Deficit Hyperactivity Disorder (ADHD) Revenue (US$ Million) & (2020-2025)
    • 7.7.5 Mallinckrodt Recent Developments
  • 7.8 Amneal Pharmaceuticals
    • 7.8.1 Amneal Pharmaceuticals Profile
    • 7.8.2 Amneal Pharmaceuticals Main Business
    • 7.8.3 Amneal Pharmaceuticals Attention Deficit Hyperactivity Disorder (ADHD) Products, Services and Solutions
    • 7.8.4 Amneal Pharmaceuticals Attention Deficit Hyperactivity Disorder (ADHD) Revenue (US$ Million) & (2020-2025)
    • 7.8.5 Amneal Pharmaceuticals Recent Developments
  • 7.9 Noven Pharmaceuticals
    • 7.9.1 Noven Pharmaceuticals Profile
    • 7.9.2 Noven Pharmaceuticals Main Business
    • 7.9.3 Noven Pharmaceuticals Attention Deficit Hyperactivity Disorder (ADHD) Products, Services and Solutions
    • 7.9.4 Noven Pharmaceuticals Attention Deficit Hyperactivity Disorder (ADHD) Revenue (US$ Million) & (2020-2025)
    • 7.9.5 Noven Pharmaceuticals Recent Developments
  • 7.10 Purdue Parma
    • 7.10.1 Purdue Parma Profile
    • 7.10.2 Purdue Parma Main Business
    • 7.10.3 Purdue Parma Attention Deficit Hyperactivity Disorder (ADHD) Products, Services and Solutions
    • 7.10.4 Purdue Parma Attention Deficit Hyperactivity Disorder (ADHD) Revenue (US$ Million) & (2020-2025)
    • 7.10.5 Purdue Parma Recent Developments
  • 7.11 Zhengdafenhai
    • 7.11.1 Zhengdafenhai Profile
    • 7.11.2 Zhengdafenhai Main Business
    • 7.11.3 Zhengdafenhai Attention Deficit Hyperactivity Disorder (ADHD) Products, Services and Solutions
    • 7.11.4 Zhengdafenhai Attention Deficit Hyperactivity Disorder (ADHD) Revenue (US$ Million) & (2020-2025)
    • 7.11.5 Zhengdafenhai Recent Developments
  • 7.12 Highland Therapeutics
    • 7.12.1 Highland Therapeutics Profile
    • 7.12.2 Highland Therapeutics Main Business
    • 7.12.3 Highland Therapeutics Attention Deficit Hyperactivity Disorder (ADHD) Products, Services and Solutions
    • 7.12.4 Highland Therapeutics Attention Deficit Hyperactivity Disorder (ADHD) Revenue (US$ Million) & (2020-2025)
    • 7.12.5 Highland Therapeutics Recent Developments
  • 7.13 Jubilant Life Sciences
    • 7.13.1 Jubilant Life Sciences Profile
    • 7.13.2 Jubilant Life Sciences Main Business
    • 7.13.3 Jubilant Life Sciences Attention Deficit Hyperactivity Disorder (ADHD) Products, Services and Solutions
    • 7.13.4 Jubilant Life Sciences Attention Deficit Hyperactivity Disorder (ADHD) Revenue (US$ Million) & (2020-2025)
    • 7.13.5 Jubilant Life Sciences Recent Developments
  • 7.14 Medice Arzneimittel Putter
    • 7.14.1 Medice Arzneimittel Putter Profile
    • 7.14.2 Medice Arzneimittel Putter Main Business
    • 7.14.3 Medice Arzneimittel Putter Attention Deficit Hyperactivity Disorder (ADHD) Products, Services and Solutions
    • 7.14.4 Medice Arzneimittel Putter Attention Deficit Hyperactivity Disorder (ADHD) Revenue (US$ Million) & (2020-2025)
    • 7.14.5 Medice Arzneimittel Putter Recent Developments
  • 7.15 Lannett
    • 7.15.1 Lannett Profile
    • 7.15.2 Lannett Main Business
    • 7.15.3 Lannett Attention Deficit Hyperactivity Disorder (ADHD) Products, Services and Solutions
    • 7.15.4 Lannett Attention Deficit Hyperactivity Disorder (ADHD) Revenue (US$ Million) & (2020-2025)
    • 7.15.5 Lannett Recent Developments

8 Industry Chain Analysis

  • 8.1 Attention Deficit Hyperactivity Disorder (ADHD) Industrial Chain
  • 8.2 Attention Deficit Hyperactivity Disorder (ADHD) Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Attention Deficit Hyperactivity Disorder (ADHD) Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Attention Deficit Hyperactivity Disorder (ADHD) Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제